#Merck’s #KEYTRUDA® (#Pembrolizumab) Approved in China for Second-Line Treatment of Patients with Locally Advanced or Metastatic #EsophagealSquamousCellCarcinoma Whose #Tumors Express #PDL1 (CPS &gt;10) $MRK https://t.co/36XekvXJ4s